Strong revenue growth masks thin margins and execution risks
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade B
Maintained FY27 revenue target (4,500 Cr) and margin guidance (7–8%); delivered numbers support execution, but thin margins and pending receivables reduce confidence.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered strong 65% revenue growth and expanded order book to ₹13,245 Cr with Adani backing, but NPM collapsed to 2.1% and EBITDA margin fell short of 7–8% guidance. Margin miss blamed on seasonal labor deficit and elevated employee costs; management expects recovery in H2. Key risk: past receivable collection issues (SDB ₹90 Cr, UP Medical ₹100 Cr) and order inflow guidance implicitly downgraded from ₹6,000–8,000 Cr to ₹4,000–5,000 Cr.
₹853.5 Cr
Revenue · +64.8% YoY₹18.3 Cr
Reported PAT · +4232.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Strong 65% YoY revenue growth despite seasonal headwinds
METDelivered 853.5 Cr vs. 518 Cr YoY, confirmed 65% growth. Q1 is seasonally weak.
EBITDA margin 6.4% reflects Q1 labor deficit, expect 7–8% in H2
PartialActual 6.4% EBITDA margin. Employees 5.39% of sales (vs. normal 4–4.5%). Explanation: Apr–May labor shortage, June revenue 319 Cr (higher). Credible but execution risk remains.
NPM improvement from 0.07% to 2.12% is substantial
METVerified: 37 lakh to 18.3 Cr YoY. But 2.12% NPM is VERY thin; breaks down to ₹55 Cr EBITDA on ₹853 Cr revenue.
Order book 13,245 Cr provides multi-year visibility; 70% from Adani
METOrder book confirmed; 70% within-group (Adani), 30% external. Concentration risk high if Adani orders slow.
Order inflows ₹4,000–5,000 Cr FY27 remain in prior range
OVERSTATEDPrior guidance ₹6,000–8,000 Cr. MD now says ₹4,000–5,000 Cr. Implicit downgrade from 6,000–8,000 to 4,000–5,000.
Debt-free within a year (prior FY26 call guidance)
MISSNow guided as 2–3 quarters (by early 2027). Long-term debt ₹38 Cr, short-term ₹217 Cr; working capital facilities still utilized ₹844 Cr. Slipping timeline.
Earnings quality
What changed since the last call
Order inflow guidance downgraded
DowngradePrior FY26 calls: ₹6,000–8,000 Cr expected. MD now implies ₹4,000–5,000 Cr FY27. Soft language ('will be in same range') masks a 25% reduction.
Debt-free timeline slipped
DowngradeFY26 guidance: 'within one year' (by June 2027). Now: 'within 2–3 quarters' (Oct–Dec 2026). Still on track but not ahead of plan.
Margin recovery pushed to H2
NeutralEBITDA margin 6.4% (vs. 7–8% guidance). Management attributes to seasonal labor deficit; expects recovery as June performance (₹319 Cr revenue) validates acceleration into core construction phase.
Employee team scaled 1.5–2x from prior year
UpgradeHeadcount 2,400 → 2,600. Employee cost 5.39% of sales (temporary excess to execute scaled order book). Management targets return to 4–4.5% as utilization improves.
The Q&A
Analysts pressed hard on margin credibility (3 questions). MD defended with detailed labor-cost breakdown but offered no guardrails. Receivables (SDB, UP Medical) mentioned without follow-up. One analyst accepted soft order inflow guidance without pushing for explicit prior-guidance retraction.
Revenue guidance reaffirmation — Shravan Shah, Dolat Capital
AnsweredYes, will be more than 25% on average, between ₹4,400–4,500 Cr. Remain in same line.
EBITDA margin timing — Shravan Shah, Dolat Capital
AnsweredH2 only due to seasonal labor deficit. April–May sales weak, June ₹319 Cr shows acceleration. If loss due to labor deficit factored in, EBITDA above 7%. Better in Q3–Q4.
Order inflow run-rate — Shravan Shah, Dolat Capital
PartialProbably same range, ±₹400–500 Cr, remains ₹4,000–5,000 range. Projects under discussion for Q2–Q3.
Working capital trajectory — Shravan Shah, Dolat Capital
AnsweredYes, we can expect so.
Mumbai project execution status — Balasubramanian, Arihant Capital
AnsweredMahim: raft foundation done, first basement floor underway. Matunga: sheet piling ongoing before excavation.
Mobilization advance terms — Balasubramanian, Arihant Capital
AnsweredThe whole amount is interest-free.
Commonwealth project timeline — Dhananjay Mishra, Centrum Broking
AnsweredNo clear timeline yet; control room just started. Probably next quarter heard. Not in FY27 order inflow guidance (government projects counted in bid pipeline only).
UP Medical receivable resolution — Dhananjay Mishra, Centrum Broking
AnsweredThree projects near EOT signing. Discussion in Lucknow last Monday. Expect EOTs by weekend/first week Aug. Money due. Account close end-Aug/mid-Sep. Unbilled ₹60 Cr + receivable ₹40 Cr will materialize.
EBITDA margin guidance upside — Ayush Saboo, Choice Institutional Equities
AnsweredH2 only. As execution speeds up in next few quarters, should be in better position to go beyond 7–8%.
SDB receivable update — Vaibhav Shah, JM Financial
DodgedNo clarity. Called for discussion with top management/board. Visiting next week. They reached out to meet but unknown positive direction. Outstanding ₹90 Cr.
Margin guidance scope (full-year vs. H2) — Vaibhav Shah, JM Financial
PartialShould be for full year. Once execution speed picks up in next quarters, should be in better position to go beyond 7–8%.
Consolidated vs. standalone revenue — Vaibhav Shah, JM Financial
AnsweredSubsidiary company executes ₹80 Cr miscellaneous Adani projects. All future guidance will be on console basis only.
Dharavi order book composition — Vishal Periwal, PL Capital
AnsweredTwo projects, ₹3,000 Cr. At ₹10–12 lakh/house (₹3,000–3,500 per sq ft), equals 30,000–32,000 houses out of total 2 lakh houses.
Dharavi follow-on opportunities — Vishal Periwal, PL Capital
AnsweredDepends on performance on current two. Foundation complexity high. Once stable on these, can always start new site. Right of first refusal if perform well.
Labor deployment scale — Vishal Periwal, PL Capital
AnsweredDifficult to compare (project-specific). Currently 16,000–17,000 needed, almost full. Peak could add 3,000–4,000 more in next 1–2 quarters as activities diversify.
Inflation impact on cost-plus contracts — Jainam Jain, Dam Capital
AnsweredMost Adani projects are pass-through cost (no impact). 30% external book (INR 5,500–6,000 Cr older projects) mostly complete. Few activities at SMC & RVNL impacted by aluminum/copper inflation; minor.
Segment diversification (new verticals post-Adani) — Jainam Jain, Dam Capital
AnsweredNo. Focus on buildings only (industry, data center, commercial, hotel, hospital). Not infrastructure or non-building work.
Geographic expansion plans — Rushabh, RBSA Investment
AnsweredNo. Focusing on Gujarat & Mumbai only. 25% non-Adani, 70–75% Adani target. Sufficient visibility for 2 years, not entering new regions yet.
Team capability scaling — Rushabh, RBSA Investment
AnsweredEmployee expense up (building team to 1.5–2x from last year). Strengthening to get more Adani orders and deliver on time.
Data center segment opportunity — Jainam Shah, Equirus Securities
PartialNot focused on Mumbai/Visakhapatnam data centers yet. Dholera (Gujarat) has two lands (data center + defense). Could come later. MediCity & housing projects (Mundra, Ahmedabad) starting soon.
Precast segment contribution — Urviben Patel, Infinite Wealth Advisors
PartialNo separate revenue tracking; embedded in project revenue. Plant capacity ₹200 Cr/year, executing ₹150–200 Cr. Margin same as overall business (Adani projects only, no other customers).
Dharavi house-count and project sizing — Shravan Shah, Dolat Capital (repeat)
AnsweredLesser number. ₹3,000 Cr, ₹10–12 lakh per house = 30,000 houses (out of 2 lakh total). Two projects building 30,000–32,000 houses now.
Tax rate normalization — Shravan Shah, Dolat Capital (repeat)
AnsweredSlightly higher due to non-deductible expenses (permanent difference). Will remain elevated vs. 25%.
Cash balance trajectory — Shravan Shah, Dolat Capital (repeat)
AnsweredYes, same level, slightly higher.
Cost-plus formula on Adani projects — Sanjay Kohli, Goldstone Capital
AnsweredCost-plus percentage on overall project cost (materials, labor, overhead). Not separate per-material margin. Total EBITDA level: Adani projects 6–7%, PSP projects 8–9%. Cost-plus effectively 7% EBITDA. Item-rate contract; material base rate quoted, actual difference paid in bill.
Cost-plus range variability — Sanjay Kohli, Goldstone Capital
AnsweredAlways 1–2% gap in execution. Standardized by project type. Mumbai +3%, Mundra +1.5%. Overhead varies by project performance (can save 1–1.5% if project runs fast).
Guidance
FY27 ₹4,400–4,500 Cr (20%+ growth)
HighOn track. Q1 seasonally weak; accelerating from June baseline. Order book ₹13,245 Cr supports full-year execution >₹4,000 Cr.
EBITDA margin 7–8% (H2 focus, full year aspiration)
MediumQ1 at 6.4% due to seasonal labor deficit & elevated employee costs. Management claims 1% margin leakage from April–May underperformance. Credible recovery if June acceleration sustains.
Employee costs normalize to 4–4.5% of revenue from current 5.39%
MediumTeam expansion (2,400 → 2,600) and April increments temporary. Normalization depends on higher absolute revenue.
Capex 3–4% of revenue
HighQ1 delivered ₹28 Cr (3.3%). MD confirms 3–4% range on average; specific large projects may spike slightly.
Risks the call surfaced
Customer concentration
High70% of order book from Adani Group. ~45% of Q1 revenue from Adani. If Adani Group orders slow or investment cycle contracts, PSP exposed to ~40% revenue drop.
Margin credibility
HighNPM at 2.1% (₹18.3 Cr on ₹853.5 Cr). EBITDA 6.4% below 7–8% guidance. Employee costs still 5.39% (vs. 4–4.5% normal). If labor inflation persists or execution slows, margins compress further.
Receivable collection
MediumSDB receivable ₹90 Cr (stuck; MD visiting next week, no timeline). UP Medical ₹100 Cr (₹60 Cr unbilled, ₹40 Cr receivable) expected to close by mid-Sep 2026. Combined ₹190 Cr at risk if customers delay further.
Execution capability
MediumQ1 saw labor deficit in Apr–May; June recovered but dependent on sustained availability. Dharavi project (30,000+ houses) is largest yet; any execution slip could damage 'right of first refusal' for phase 2. SMC & RVNL impacted by aluminum/copper inflation.
Guidance credibility
MediumPrior FY26 guidance: ₹6,000–8,000 Cr order inflows. Current call implies ₹4,000–5,000 Cr. MD used soft language ('same range') but new numbers are lower. If H2 misses even ₹4,000–5,000 Cr target, credibility dents further.
Management
Score 6/10. Clear on execution updates & project-level details. Defensive on margin misses; used technical explanations (seasonal labor deficit, employee scaling) to justify shortfalls. Evasive on SDB receivable (no timeline). Met revenue growth target (65% YoY). Missed EBITDA margin guidance (6.4% vs. 7–8%). Implicit downgrade on order inflows (₹6,000–8,000 → ₹4,000–5,000). Past receivable collection issues (SDB, UP Medical) not fully resolved.
1 · Q2–Q3 FY27
Labor normalization & H2 margin recovery to 7–8% EBITDA target
2 · Aug–Sep 2026
UP Medical ₹100 Cr receivable materialization; SDB ₹90 Cr resolution
3 · H2 FY27
Commonwealth Games Ahmedabad tender (uncertain timing, not in FY27 order inflow guidance)
Key risk: past receivable collection issues (SDB ₹90 Cr, UP Medical ₹100 Cr) and order inflow guidance implicitly downgraded from ₹6,000–8,000 Cr to ₹4,000–5,000 Cr.
Informational and educational content only. Not investment advice.